Christopher G. Nasveschuk

C4 Therapeutics (United States) — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

23h-index2.1kcitations70works1.42yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Protein Degradation and Inhibitors(33), Multiple Myeloma Research and Treatments(15), Ubiquitin and proteasome pathways(13), Histone Deacetylase Inhibitors Research(13), Synthetic Organic Chemistry Methods(12)

Publications70 total

Design, synthesis and biological evaluation of macrocyclic NTRK heterobifunctional degraders
Bioorganic & Medicinal Chemistry Letters·2026
CCDC 2487039: Experimental Crystal Structure Determination
The Cambridge Structural Database·2025Open Access
Discovery of CFT8634, a Potent, Selective, and Orally Bioavailable Heterobifunctional Degrader of BRD9
Journal of Medicinal Chemistry·2025· 3 cited
A DRUG HUNTER’S APPROACH TO MOLECULAR GLUES
Medicinal chemistry reviews·2025
CFT1946 Is an Orally Available Brain-Penetrant BRAFV600-Mutant Degrader That Overcomes BRAF Inhibitor Resistance
Cancer Research·2025· 1 cited
CFT8634, a potent, selective and orally bioavailable BiDACTM degrader of BRD9, highlights the potential of C4T’S TORPEDO® platform to develop degraders with excellent drug-like properties against currently undruggable targets
Drug Metabolism and Pharmacokinetics·2025
Determination of steady state brain KP,UU of BIDAC(TM) degraders using chemical knock out animal models
Drug Metabolism and Pharmacokinetics·2025
Mechanistic insights into a heterobifunctional degrader-induced PTPN2/N1 complex
Communications Chemistry·2024· 7 citedOpen Access
CFT7455, a novel IKZF1/3 degrader, demonstrates potent activity in peripheral and CNS models of NHL as a single agent or in combination with clinically approved agents
Hematological Oncology·2023· 5 citedOpen Access
Abstract ND05: The discovery and characterization of CFT1946: A potent, selective, and orally bioavailable degrader of mutant BRAF for the treatment of BRAF-driven cancers
Cancer Research·2023· 1 cited
Abstract 3425: The discovery and characterization of CFT1946: A potent, selective, and orally bioavailable degrader of mutant BRAF for the treatment of BRAF-driven cancers
Cancer Research·2023· 10 cited
Data from Preclinical Development of the Class-I–Selective Histone Deacetylase Inhibitor OKI-179 for the Treatment of Solid Tumors
2023Open Access
Supplementary Figure from Preclinical Development of the Class-I–Selective Histone Deacetylase Inhibitor OKI-179 for the Treatment of Solid Tumors
2023Open Access
Data from Preclinical Development of the Class-I–Selective Histone Deacetylase Inhibitor OKI-179 for the Treatment of Solid Tumors
2023Open Access
Supplementary Data from Preclinical Development of the Class-I–Selective Histone Deacetylase Inhibitor OKI-179 for the Treatment of Solid Tumors
2023Open Access
Supplementary Data from Preclinical Development of the Class-I–Selective Histone Deacetylase Inhibitor OKI-179 for the Treatment of Solid Tumors
2023Open Access
Supplementary Figure from Preclinical Development of the Class-I–Selective Histone Deacetylase Inhibitor OKI-179 for the Treatment of Solid Tumors
2023Open Access
CFT7455, a Novel IKZF1/3 Degrader, Demonstrates Potent Anti-Tumor Activity in Models of Non-Hodgkin's Lymphoma As a Single Agent or in Combination with Clinically Approved Agents
Blood·2022· 4 cited
GNE-064: A Potent, Selective, and Orally Bioavailable Chemical Probe for the Bromodomains of SMARCA2 and SMARCA4 and the Fifth Bromodomain of PBRM1
Journal of Medicinal Chemistry·2022· 20 citedOpen Access
Abstract ND13: The discovery and characterization of CFT7455: A potent and selective degrader of IKZF1/3 for the treatment of relapsed/refractory multiple myeloma
Cancer Research·2022· 3 cited
page 1 of 4Next →

Frequent Co-authors

Brian K. Albrecht(16), James E. Audia(16), Stewart L. Fisher(16), Andrew J. Phillips(15), Roman V. Agafonov(14), Andrew C. Good(13), Alexandre Côté(12), Richard Cummings(12), Alexander M. Taylor(12), Scott J. Eron(12), Michael C. Hewitt(11), Roy M. Pollock(11), S.F. Bellon(10), Eneida Pardo(10), Jean-Christophe Harmange(10), Tomislav Rovis(10), Victor Gehling(9), Rishi G. Vaswani(9), Péter Sandy(9), Ashley Hart(9)